Dear Shareholders,The year 2025 marked a pivotal chapter in our strategic transformation, representing a new phase of ...
FDA issues Complete Response Letter for RGX-121 (clemidsogene lanparvovec) for treatment of Mucopolysaccharidosis II (MPS II) REGENXBIO plans to work with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results